A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative

Documenti analoghi

• Efficacy and safety of PD‐1/PD‐L1 inhibitors in elderly patients with advanced non‐small cell lung cancer
  di: Li Li, et al.
  Pubblicazione: (2024)
• Efficacy and safety of novel immune checkpoint inhibitor‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis
  di: Chuang Yang, et al.
  Pubblicazione: (2024)
• In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
  di: Linda Wanika, et al.
  Pubblicazione: (2024)
• Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study
  di: Runbo Zhong, et al.
  Pubblicazione: (2025)
• Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer
  di: Ayako Morita, et al.
  Pubblicazione: (2024)